Skip to main content

Pay Bill Portals

Our Tests
Our Services
- - Oncology
    - - SERVICES
        
        NateraCore Services
        
        Pharma Partnership
        
        Real-World Data
        
        EMR Integration
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
        
        Contact Us
    - - FOR CLINICIANS
        
        Schedule Session With Client Services
        
        Oncology Portal
        
        Order a Test Kit
        
        Contact Us
  - Organ Health
    - - SERVICES
        
        NateraCore Services
        
        ProReach
        
        EMR Integration
        
        Pharma Services
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Order a Renasight Kit
        
        Contact Us
        
        Pricing and Billing Information
    - - FOR CLINCIANS
        
        Organ Health Portal
        
        Order a Renasight Kit
        
        Contact Us
  - Women’s Health
    - - SERVICES
        
        NateraCore Services
        
        Constellation
        
        EMR Integration
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Pricing and Billing Information
        
        Women’s Health Portal
        
        Contact Us
    - - FOR CLINICIANS
        
        Order Tests and Track Status on NateraConnect
        
        View Patient Results on NateraConnect
        
        Contact Us
  - Rare Disease
    - - SERVICES
        
        EMR Integration
    - - FOR PATIENTS
        
        Schedule a Zenith™ Genetic Information Session
        
        Billing Information
    - - FOR CLINICIANS
        
        Rare Disease Portal
        
        Order a Test Kit
        
        Contact Us
Patient Resources
- - Oncology
    - - LEARN
        
        Signatera
        
        Altera
        
        Empower
        
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
    - - CONNECT
        
        Contact Us
  - Organ Health
    - - LEARN
        
        Prospera
        
        Renasight
        
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule a Genetic Information Session
        
        Pricing and Billing Information
    - - CONNECT
        
        Contact Us
  - Women’s Health
    - - LEARN
        
        Horizon
        
        Panorama
        
        Empower
        
        Vistara
        
        Anora
        
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Blood Draw (Existing Patients – USA)
        
        Schedule Blood Draw (Existing Patients – Canada)
        
        Pricing and Billing Information
        
        Women’s Health Portal
    - - CONNECT
        
        Contact Us
  - Rare Disease
    - - EXISTING PATIENTS
        
        Schedule a Zenith™ Genetic Information Session
        
        Billing Information
Clinical Resources
- - Oncology
    - - CLINICAL RESOURCES
        
        Signatera
        
        Signatera Publications
        
        Altera
        
        Empower
        
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        Signatera Research Pipeline
        
        Natera Sponsored Trials
    - - CONNECT
        
        Oncology Portal
        
        Contact Us
  - Organ Health
    - - CLINICAL RESOURCES
        
        Organ Health Publications
        
        Prospera
        
        Renasight
        
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        ProActive Study
        
        PEDAL Study
        
        Trifecta Study
        
        MOTR Study
    - - CONNECT
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - CLINICAL RESOURCES
        
        Women’s Health Publications
        
        Horizon
        
        Panorama
        
        Empower
        
        Vistara
        
        Anora
        
        Natera Academy Provider Education Hub
        
        View All Clinician Resources
    - - RESEARCH STUDIES
    - - CONNECT
        
        Contact Us
  - Rare Disease
    - - CLINICAL RESOURCES
        
        Zenith™ Clinician Information
    - - CONNECT
        
        Rare Disease Portal
        
        Contact Us
Company
Search for:
Pay Bill

Portals
Search for:

Natera, Inc.

- Altera
- Anora
- Empower
- Horizon
- Panorama
- Prospera
- Renasight
- Signatera
- Spectrum
- Vistara
- Blog
- Videos
- Brochure
- Whitepaper
- Manual
- Poster
- Report
- Study
- Webinars
- Natera Academy

Recent Searches

Home
Poster
Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t

Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t

Published Date September 22, 2026

Previous Resource

Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy

Puzstai L, Scalise CB, Kalashnikova E, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
No More Resources of this Type

Related Content

Circulating tumor DNA monitoring in participants with ovarian cancer treated with neoadjuvant pembrolizumab plus chemotherapy with or withou

Lee J-Y, Ibañez C; Bidzinski M, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Feasibility of adjuvant therapy guided by circulating tumor DNA-based molecular residual disease (ctDNA-MRD) for stage II-III gastric cancer

Liu L, Li S, Qu H, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Real-world analysis of ctDNA and other biomarkers in patients with curatively resected Stage I-III Biliary Tract Cancer

Abdelrahim M, Esmail A, Tin A, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Early treatment ctDNA dynamics to predict response to chemotherapy in patients with metastatic pancreatic cancer: a prospective, observation

Lee JY, Sidiqi B, Battaglia J, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer

Malla M, Aushev VN, Ramu A, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Exome analysis of over 5000 esophagogastric cancers

Mukherji R, Aushev VN, Rivero-Hinojosa S, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage

Montagut M, Tamberi S, Leone F, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA

Shen JPYC, Reiter JR, Babiarz J, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Impact of Perioperative Complications on MRD Detection and Prognosis Using ctDNA: Insights from the GALAXY Study

Oki E, Sato S, Ando K, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Circulating tumor DNA as an early response indicator in anal squamous cell carcinoma treated with chemoradiation

Bercz A, Alvarez J, Kostrzewa CE, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma

Zhou M, Nam Bui N, Pan M, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Early on-treatment ctDNA dynamics and response by imaging in patients with sarcoma

Victor A. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Circulating tumor DNA monitoring in patients with advanced urothelial carcinoma treated with Enfortumab Vedotin +/- Pembrolizumab

Reyes KR, Jindal T, Mitchell B, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Association of Tumor-Informed ctDNA-based Molecular Residual Disease (MRD) with Clinical Outcomes for Upper Tract Urothelial Cancer (UTUC)

Ayanambakkam A, Laliotis G, Reyes K, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA

Powles T, van der Heijden MS, Wang Y, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
EORTC2129-BCG: elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (Treat ctDNA trial).

Ignatiadis M, Saloustros E, Joaquim A, et al. ASCO Annual Meeting 2025, Chicago, IL. M

Read More
over 1 year ago
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant lasofoxifene in molecularly selected patients with hormone receptor positive (HR+)/HE

Wei M, Elias AD, Giridhar K, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Circulating tumor DNA in patients with stage 2/3 HR+HER2-negative breast cancer receiving neoadjuvant endocrine therapy in the I-SPY2 Endocr

Alkhafaji S, Magbanua MJM, van ‘t Veer L, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: results from the I-SPY2 t

Mukhtar RA, Santos-Parker K, Santos-Parker J, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More
over 1 year ago
Cadence of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC)

Lipsyc-Sharf M, Cheng C, Medford A, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.

Read More

Return to Resource Library

© Natera, Inc.

Our Tests
Our Services
Patient Resources
Clinical Resources
- Resource Library
- Provider Portals
Company
Contact

Natera Licenses
IT Security Compliance
Natera Notice of Data Collection for California Residents
HIPAA Notice of Privacy Practices
Privacy Policy
Terms of Use
Sitemap

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.